These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1328 related articles for article (PubMed ID: 30281045)
1. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]. Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045 [TBL] [Abstract][Full Text] [Related]
4. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
6. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
7. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Yandrapalli S; Andries G; Biswas M; Khera S Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791 [TBL] [Abstract][Full Text] [Related]
8. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Lillyblad MP Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499 [TBL] [Abstract][Full Text] [Related]
9. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. Nguyen E; Weeda ER; White CM J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162 [TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. Rodgers JE Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069 [TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. King JB; Shah RU; Bress AP; Nelson RE; Bellows BK JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128 [TBL] [Abstract][Full Text] [Related]
14. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Jhund PS; McMurray JJ Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980 [TBL] [Abstract][Full Text] [Related]
15. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System. Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903 [TBL] [Abstract][Full Text] [Related]
17. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ; Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. Chin KL; Zomer E; Wang BH; Liew D Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468 [TBL] [Abstract][Full Text] [Related]
19. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. Sokos GG; Raina A Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]